ASCO GI 2024 | PROOF 301: infigratinib vs. gem/cis in patients with CCA with an FGFR2 gene fusion/rearrangement

Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, presents findings on infigratinib as a potential frontline treatment for FGFR2 gene fusion/translocations in cholangiocarcinoma (CCA). The PROOF 301 (NCT03773302) Phase III trial, comparing infigratinib to gemcitabine + cisplatin, was prematurely halted, and this report covers the accrued patient data before termination. Of the 48 enrolled patients, 29 received infigratinib, and 19 received gem/cis. Preliminary results indicate a median progression-free survival (PFS) of 7.4 months with infigratinib versus 8.0 months with gem/cis. Infigratinib demonstrated a higher overall response rate (37.9%) compared to gem/cis (15.8%). Despite early termination, the study suggests infigratinib’s potential efficacy in FGFR2-rearranged CCA. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.